UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

~~Report~~REPORT ofOF ~~Foreign~~FOREIGN ~~Private~~PRIVATE ~~Issuer~~ISSUER

~~Pursuant~~PURSUANT toTO ~~Rule~~RULE ~~13a~~13A-16 orOR ~~15d~~15D-16

~~Under~~UNDER ~~the~~THE ~~Securities~~SECURITIES ~~Exchange~~EXCHANGE ~~Act~~ACT ofOF 1934

For the month of ~~July~~August 2025.

Commission File Number 001-40772

Cellebrite DI Ltd.

(Translation of registrant’s name into English)

94 Shlomo Shmelzer Road

Petah Tikva 4970602, Israel

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

EXPLANATORY NOTE

OnThis ~~July~~Report 8,of ~~2025,~~Foreign Private Issuer on Form 6-K (this “Form 6-K”) filed by Cellebrite DI Ltd. (the “~~Registrant~~Company” ~~or “Cellebrite”~~) ~~issued~~consists aof ~~press~~the ~~release~~Company’s: (i) consolidated financial statements for the ~~“Press~~six ~~Release”)~~months ~~titled~~ended ~~“Cellebrite Names~~June 30, ~~David~~2025, ~~Barter~~which ~~Chief~~are ~~Financial~~attached ~~Officer~~hereto as Exhibit 99.1 ~~CFO~~and ~~Dana~~are ~~Gerner~~incorporated toby ~~Retire”.~~reference Aherein; and ~~copy~~(ii) ofoperating ~~the~~and ~~press~~financial ~~release~~review isand ~~attached~~prospects to(unaudited) ~~this~~for ~~Report~~the ~~on Form~~six ~~6-K~~months ended June 30, 2025, which are attached hereto as Exhibit 99.12 and are incorporated by reference herein.

~~The~~This ~~first~~Form ~~paragraph~~6-K, ofincluding ~~the~~its ~~Press~~exhibits, ~~Release~~ is incorporated by reference into the ~~Registrant~~Company’s registration statements on Form SF-83 (File ~~Nos~~No. 333-~~260878 and 333-278130~~259826) filed with the U.S. Securities and Exchange Commission (the “SEC”) on ~~November~~September 813, ~~2021~~2022 and ~~March 21, 2024, respectively, and~~ Form FS-3 8 (File NoNos. 333-~~259826~~260878 and 333-278130) filed with the SEC on ~~September~~November 138, ~~2022,~~2021 toand beMarch a21, ~~part thereof from the date on which this Report on Form 6-K is submitted~~2024, ~~to the extent not superseded by documents or reports subsequently filed or furnished~~respectively.

EXHIBIT INDEX

Exhibit		Description
Exhibit No.		Exhibit
99.1		~~Press~~Consolidated ~~release~~financial ~~titled~~statements “of Cellebrite ~~Names~~DI ~~David~~Ltd. ~~Barter~~and ~~Chief~~its ~~Financial~~subsidiaries ~~Officer.~~for ~~CFO~~the ~~Dana~~six-months ~~Gerner~~ended toJune ~~Retire”~~30, 2025.
99.2		Operating and Financial Review and Prospects for the six months ended June 30, 2025.
101.INS		Inline XBRL Instance Document.
101.SCH		Inline XBRL Taxonomy Extension Schema Document.
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Cellebrite DI Ltd.
Date: July 8, 2025	By:	/s/ Ayala Berler Shapira
August 14, 2025	By:	/s/ David Barter
		Ayala Berler Shapira, Adv.
		David Barter
		General Counsel
		Chief Financial Officer

Filing Compare · Cellebrite DI Ltd.